Display options
Cite
Kim JS, Jeong SH, Kim DH, et al. Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis. J Clin Neurol. 2005;1(2):134-41doi: 10.3988/jcn.2005.1.2.134.
Kim, J. S., Jeong, S. H., Kim, D. H., & Kim, J. (2005). Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis. Journal of clinical neurology (Seoul, Korea), 1(2), 134-41. https://doi.org/10.3988/jcn.2005.1.2.134
Kim, Ji Seon, et al. "Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis." Journal of clinical neurology (Seoul, Korea) vol. 1,2 (2005): 134-41. doi: https://doi.org/10.3988/jcn.2005.1.2.134
Kim JS, Jeong SH, Kim DH, Kim J. Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis. J Clin Neurol. 2005 Oct;1(2):134-41. doi: 10.3988/jcn.2005.1.2.134. Epub 2005 Oct 20. PMID: 20396460; PMCID: PMC2854918.
Copy Download .nbib Format: NLM
Share it on

J Clin Neurol. 2005 Oct;1(2):134-41. doi: 10.3988/jcn.2005.1.2.134. Epub 2005 Oct 20.

Safety and feasibility of subcutaneous low molecular weight heparin for cerebral venous sinus thrombosis.

Journal of clinical neurology (Seoul, Korea)

Ji Seon Kim, Seong Hae Jeong, Dae Hyun Kim, Jei Kim

Affiliations

  1. Department of Neurology, College of Medicine, Chungnam National University, Daejeon, Korea.

PMID: 20396460 PMCID: PMC2854918 DOI: 10.3988/jcn.2005.1.2.134

Abstract

BACKGROUND AND PURPOSE: The effect of low molecular weight heparin (LMWH) in the management of cerebral venous thrombosis (CVT) remains unclear. The present study was performed to determine the safety and feasibility of subcutaneous LMWH, with particular attention to hemorrhagic conversions.

METHODS: LMWH (nadroparin, 7,500 ICU, every 12 hours) was administered subcutaneously for 14 days to 12 patients diagnosed with CVT. Initial clinical manifestations, etiologies and the clinical courses after LMWH treatment were also evaluated. Possible hemorrhagic side effects, including aggravation of the initial hemorrhage and/or newly developed-hemorrhagic conversions were monitored by image analysis.

RESULTS: Headaches and convulsive movements were frequent presenting symptoms for CVT. Clinical improvement was usually observed within 2 to 8 days after LMWH. Symptom stabilization was observed within 4 to 60 days. Neither clinical aggravations, nor newly developed parenchymal lesions were observed during LMWH maintenance. Associated parenchymal lesions were observed in 9 of the 12 patients, 5 of which manifested with hemorrhagic conversion, as detected by image analysis. However, no clinical and radiologic aggravation was noted in these 5 patients.

CONCLUSIONS: Our results suggest that LMWH may be safe and feasible in the management of CVT.

Keywords: Cerebral venous sinus thrombosis; Low-molecular-weight heparin; Unfractionated heparin

References

  1. N Engl J Med. 1997 Sep 4;337(10):688-98 - PubMed
  2. Lancet. 1991 Nov 2;338(8775):1154 - PubMed
  3. Am Heart J. 2002 Jun;143(6):952-60 - PubMed
  4. J Thromb Haemost. 2005 Mar;3(3):473-81 - PubMed
  5. JAMA. 2004 Jul 7;292(1):101-3 - PubMed
  6. Arch Neurol. 1988 May;45(5):567-72 - PubMed
  7. Stroke. 1987 May-Jun;18(3):656-60 - PubMed
  8. JAMA. 2004 Jul 7;292(1):55-64 - PubMed
  9. Lancet. 1991 Sep 7;338(8767):597-600 - PubMed
  10. Am J Med. 1996 Mar;100(3):269-77 - PubMed
  11. J Thromb Haemost. 2003 Sep;1(9):1906-13 - PubMed
  12. Neurol Clin. 1992 Feb;10(1):87-111 - PubMed
  13. N Engl J Med. 1991 May 30;324(22):1565-74 - PubMed
  14. Br J Surg. 1995 Apr;82(4):496-501 - PubMed
  15. Thromb Haemost. 1989 Dec 29;62(4):1046-9 - PubMed
  16. Cerebrovasc Dis. 1998 Nov-Dec;8(6):331-7 - PubMed
  17. J Bone Joint Surg Br. 1991 May;73(3):434-8 - PubMed
  18. Stroke. 2003 Apr;34(4):1054-5 - PubMed
  19. CMAJ. 1998 Oct 20;159(8):931-8 - PubMed
  20. Stroke. 1999 Mar;30(3):484-8 - PubMed
  21. Thromb Haemost. 1998 Feb;79(2):259-63 - PubMed
  22. Thromb Haemost. 1994 Aug;72(2):186-90 - PubMed
  23. Lancet. 1991 Nov 2;338(8775):1153-4 - PubMed
  24. Arch Intern Med. 1995 Mar 27;155(6):601-7 - PubMed
  25. Ann Intern Med. 2004 Feb 3;140(3):175-83 - PubMed
  26. Circulation. 2004 Dec 14;110(24 Suppl 1):IV13-9 - PubMed
  27. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):1-3 - PubMed

Publication Types